News
March 30, 2023

Study assesses prevalence, severity, co-occurrence of common symptoms undertreated in cancer patients

Researchers also survey association of symptoms with various cancer types and patient characteristics

Managing symptoms improves quality of life. Sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy/fatigue – known collectively as the SPPADE symptoms – are common, co-occurring, and undertreated in cancer patients. A large population study by Regenstrief Institute, Mayo Clinic and Yale University researchers examines the prevalence, severity, and co-occurrence of SPPADE symptoms as well as their association with cancer type and patient characteristics.

A total of 31,886 cancer patients were interviewed and assessed for SPPADE symptoms prior to, during or soon after an outpatient medical oncology appointment. Symptoms were pervasive across all types of cancer and sociodemographics.

Among the study findings about the six SPPADE symptoms:

  • Type of cancer was associated with modest differences in symptom burden, with higher symptom burden among patients with lung, gastrointestinal (other than colon), and gynecologic cancers.
  • Symptom burden was generally similar across most sociodemographics.
  • Older patients did not report higher symptom rates.
  • Rates of symptoms did not differ by sex.
  • There was a modest association of symptom burden with
    • disabled employment status
    • Medicaid as a payor
    • lower educational attainment.
  • The proportion of patients with symptoms ranged from 17.5 percent for depression to 33.4 percent for fatigue.
  • Co-occurring symptoms were significantly more common than a single symptom: The proportion of patients with three or more symptoms ranged from 45.2 percent for fatigue to 68.6 percent for depression.

“It’s understandable that during a busy appointment, discussions of symptoms tend to focus on those that the physician considers more directly attributable to their disease and its treatment – such as nausea, vomiting, mouth sores, neuropathy – rather than SPPADE symptoms,” said Regenstrief Institute and Indiana University School of Medicine Research Scientist Kurt Kroenke, M.D., corresponding author of the new study. “But it’s important for cancer patients to know sleep disturbance, pain, physical function impairment, anxiety, depression and low energy/fatigue, while, perhaps, related to other factors in addition to their cancer, are not uncommon and that we have simple ways of measuring and effective ways of managing these often-debilitating symptoms.”

Dr. Kroenke is a pioneer and international leader in the field of symptomology. He has co-developed brief survey measures in worldwide use to track symptoms of depression (PHQ-9); anxiety (GAD-7); suicide risk (P-4); and conditions common in older adults (SymTrak). Some of these tools, which assist clinicians in selecting treatments and evaluating their effectiveness, have been translated into more than 100 languages. He recently co-developed a brief item scale (the FSI-3) to measure cancer fatigue.

The study authors note, “Because SPPADE symptoms are highly prevalent and their effects relate more to morbidity and quality of life than mortality, it is important to minimize overdiagnosis while at the same time optimizing treatment in patients most needing or desiring treatment. Thus, prioritizing symptoms that warrant treatment should integrate several factors including symptom characteristics (severity, time course, treatability, rapidity of response) as well as patient preferences.”

Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients with Cancer” is published in Journal of Pain and Symptom Management.

This research is supported by the National Cancer Institute of the National Institutes of Health, award UM1 CA 233033.

Authors and affiliations
Kurt Kroenke1, Veronica Lam2, Kathryn J. Ruddy3, Deirdre R. Pachman4, Jeph Herrin5, Parvez A. Rahman6, Joan M. Griffin7, Andrea L. Cheville8

  • 1 Indiana University School of Medicine (K.K.), Indianapolis, Indiana, USA; Regenstrief Institute, Inc. (K.K.), Indianapolis, Indiana, USA.
  • 2 Department of Physical Medicine and Rehabilitation (V.L., A.L.C.), Mayo Clinic, Rochester, Minnesota, USA.
  • 3 Division of Medical Oncology (K.J.R.), Mayo Clinic, Rochester, Minnesota, USA.
  • 4 Division of Community Internal Medicine, Geriatrics, and Palliative Care (D.R.P.), Mayo Clinic, Rochester, Minnesota, USA.
  • 5 Yale University School of Medicine (J.H.), New Haven, Connecticut, USA.
  • 6 Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (P.A.R., J.M.G., A.L.C.), Mayo Clinic, Rochester, Minnesota, USA.
  • 7 Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (P.A.R., J.M.G., A.L.C.), Mayo Clinic, Rochester, Minnesota, USA; Division of Health Care Delivery Research (J.M.G.), Mayo Clinic, Rochester, Minnesota, USA.
  • 8 Department of Physical Medicine and Rehabilitation (V.L., A.L.C.), Mayo Clinic, Rochester, Minnesota, USA; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (P.A.R., J.M.G., A.L.C.), Mayo Clinic, Rochester, Minnesota, USA.

About Kurt Kroenke, M.D.
In addition to his role as a research scientist at Regenstrief Institute, Kurt Kroenke, M.D., is director of the Master of Science in Clinical Research program and a professor of medicine at Indiana University School of Medicine.

About Regenstrief Institute
Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute’s research mission.

About IU School of Medicine
IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.

Related News

Equitable opportunity for transplants: Experts provide disparity-sensitive measures for transplant centers

Equitable opportunity for transplants: Experts provide disparity-sensitive measures for transplant centers

INDIANAPOLIS – An Expert Insight, published in the journal Transplantation, highlights health equity, disparity and inequality in organ transplantation

Dawn Bravata, MD

Study provides blueprint for hybrid-virtual home visit model to support patients who do not live close to a hospital

In a new study, U.S. Department of Veteran Affairs (VA), Regenstrief Institute, and Indiana University School of Medicine research

Regenstrief Institute President and CEO gives commencement speech at UW-Green Bay

Regenstrief Institute President and Chief Executive Officer Rachel Patzer, PhD, MPH, spoke to students graduating from the University of